Vigil Neuroscience (NASDAQ:VIGL) Given “Market Outperform” Rating at JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Vigil Neuroscience (NASDAQ:VIGL) in a research note issued to investors on Tuesday morning,Benzinga reports. JMP Securities currently has a $22.00 price target on the stock.

Several other equities research analysts also recently issued reports on the company. Wedbush increased their price target on Vigil Neuroscience from $23.00 to $24.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. HC Wainwright restated a “buy” rating and set a $17.00 target price on shares of Vigil Neuroscience in a report on Friday, November 8th. Finally, Guggenheim cut their price target on shares of Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat.com, Vigil Neuroscience presently has an average rating of “Moderate Buy” and an average target price of $16.60.

Vigil Neuroscience Stock Up 7.4 %

VIGL opened at $2.47 on Tuesday. The stock has a market cap of $100.97 million, a P/E ratio of -1.20 and a beta of 1.92. Vigil Neuroscience has a 12 month low of $2.08 and a 12 month high of $6.06. The company has a fifty day simple moving average of $3.40 and a 200 day simple moving average of $3.63.

Hedge Funds Weigh In On Vigil Neuroscience

A number of large investors have recently bought and sold shares of VIGL. Point72 Asset Management L.P. lifted its position in Vigil Neuroscience by 7.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company’s stock worth $5,440,000 after buying an additional 115,000 shares in the last quarter. Vanguard Group Inc. raised its holdings in Vigil Neuroscience by 11.9% during the first quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock worth $3,050,000 after acquiring an additional 95,276 shares in the last quarter. Ensign Peak Advisors Inc raised its holdings in Vigil Neuroscience by 72.8% during the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock worth $1,580,000 after acquiring an additional 166,442 shares in the last quarter. abrdn plc acquired a new position in Vigil Neuroscience during the third quarter valued at approximately $799,000. Finally, Geode Capital Management LLC grew its stake in Vigil Neuroscience by 41.9% in the third quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock valued at $769,000 after purchasing an additional 66,712 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.